NASDAQ:HYPD Hyperion DeFi Q4 2025 Earnings Report $3.24 +0.32 (+10.96%) Closing price 04:00 PM EasternExtended Trading$3.24 0.00 (0.00%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Hyperion DeFi EPS ResultsActual EPS-$7.76Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AHyperion DeFi Revenue ResultsActual Revenue$0.50 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AHyperion DeFi Announcement DetailsQuarterQ4 2025Date3/26/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Hyperion DeFi Earnings HeadlinesAnalysts Conflicted on These Healthcare Names: Aveanna Healthcare Holdings (AVAH), Kura Oncology (KURA) and Hyperion DeFi (HYPD)June 12, 2026 | theglobeandmail.comHyperion DeFi Reiterates Guidance on Sunset of USDH and Felix MarketsJune 8, 2026 | markets.businessinsider.comRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the largest mineral reserve in the country - enough gold for a new Fort Knox, enough copper to rebuild the U.S. electric grid 25 times over. The Trump administration has previously staked positions in MP Materials, Lithium America, Trilogy Metals, and USA Rare Earth - each time shares moved higher. A landmark policy decision expected before June 30 could reprice this stock from $2 to $20 or more within a year.June 16 at 1:00 AM | Paradigm Press (Ad)Hyperion DeFi, Inc. Maintains 2026 Financial Guidance Despite Partnership Changes with Native Markets and Felix MarketsJune 8, 2026 | quiverquant.comQHyperion DeFi Reiterates Guidance on Sunset of USDH and Felix MarketsJune 8, 2026 | globenewswire.comHyperion DeFi Inc HYPDMay 20, 2026 | morningstar.comMSee More Hyperion DeFi Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Hyperion DeFi? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hyperion DeFi and other key companies, straight to your email. Email Address About Hyperion DeFiEyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.View Hyperion DeFi ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Okta’s AI Moment May Be Bigger Than Investors RealizeStrategy’s Bitcoin Rally Has a Hidden EngineIs Lennar Finally Turning the Corner After Its Housing Slump?Can D-Wave Hold Its Own Against 2 Fast-Growing Rivals?This Golden Cross Could Send Urban Outfitters to New Highs3 Dividend Increases Investors Can Actually TrustRH’s Strong Q1 Still Leaves Investors With One Big Question Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
